Journal of Clinical Psychopharmacology · 2019 · 25 citations · 21 references
MedicinePharmacologyPsychiatryClinical PharmacologyPharmacovigilancePsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDepression ManagementDepression PharmacotherapyAdjunctive Antidepressant TherapyAntidepressant AdjuvantsAntidepressant EfficacyAntidepressant MedicationsAntidepressant SafetyAntidepressant TolerabilityClinical Rating ScalesOpen-label Trials
BACKGROUND: Long-term treatment is recommended in major depressive disorder (MDD) to prevent relapse and to restore functioning. The aim of this study (Orion; NCT01360866) was to assess the long-term safety, tolerability, and efficacy of open-label treatment with adjunctive brexpiprazole in adult patients with MDD. METHODS: Patients rolled over into this 52-week study (amended to 26 weeks) from 3 randomized, double-blind, placebo-controlled studies. Patients received brexpiprazole 0.5 to 3 mg/d (flexible dose) adjunct to their current antidepressant treatment. The primary outcome variable was the frequency and severity of treatment-emergent adverse events (TEAEs). Efficacy was assessed as a secondary objective using clinical rating scales. RESULTS: A total of 2944 patients were enrolled (1547 for 52 weeks, 1397 for 26 weeks), of whom 1895 (64.4%) completed the study. The TEAEs with incidence of 5% or greater were weight increase (17.7%), somnolence (8.0%), headache (7.2%), akathisia (6.7%), increased appetite (6.3%), insomnia (6.3%), fatigue (6.1%), viral upper respiratory tract infection (5.4%), and anxiety (5.2%). Most TEAEs were mild or moderate in severity. The mean increase in body weight was 2.7 kg to week 26 and 3.2 kg to week 52; 25.8% of patients had a weight increase of 7% or greater at any postbaseline visit. There were no clinically relevant findings related to extrapyramidal symptoms, prolactin, lipids, or glucose. Patients' symptoms and functioning showed continual improvement. CONCLUSIONS: Adjunctive treatment with open-label brexpiprazole 0.5 to 3 mg/d was generally well tolerated for up to 52 weeks in patients with MDD and was associated with continued improvement in efficacy measures and functional outcomes.
21
Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate et al. · The Lancet · 2017 · 13.5K citations · Full text
Kelly Posner, Gregory K. Brown, Bárbara Stanley et al. · American Journal of Psychiatry · 2011 · 5K citations
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
G. M. Simpson, M. B., GH. B. et al. · Acta Psychiatrica Scandinavica · 1970 · 3.3K citations
Medicine, Pharmacology, Psychiatry +10
The Inventory of Depressive Symptomatology (IDS): psychometric properties
A. John Rush, Christina M. Gullion, Monica Ramirez Basco et al. · Psychological Medicine · 1996 · 2.2K citations